Information Provided By:
Fly News Breaks for December 5, 2019
AUPH
Dec 5, 2019 | 07:27 EDT
Oppenheimer analyst Justin Kim raised his price target for Aurinia Pharmaceuticals to $22 from $14 following the release of top-line Phase 3 AURORA results with voclosporin in lupus nephritis. In a research note to investors, Kim says that in addition to establishing strong efficacy benefit in complete renal response rate, a robust tolerability and safety profile was presented. In light of these data, Kim says he expects focus to quickly shift to the large addressable commercial potential in LN and regulatory timelines.
News For AUPH From the Last 2 Days
There are no results for your query AUPH
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.